Healios KK (JP:4593)
:4593
Want to see JP:4593 full AI Analyst Report?
4593 Stock Chart & Stats
¥370.00
¥3.00(1.60%)
At close: 4:00 PM EST
¥370.00
¥3.00(1.60%)
Day’s Range― - ―
52-Week Range¥255.00 - ¥747.00
Previous CloseN/A
Volume811.70K
Average Volume (3M)1.65M
Market Cap
¥46.44B
Enterprise Value¥34.18B
Total Cash (Recent Filing)¥5.68B
Total Debt (Recent Filing)¥2.61B
Price to Earnings (P/E)3.6
Beta1.12
Next Earnings
May 20, 2026EPS Estimate
-11.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.25
Shares Outstanding135,002,200
10 Day Avg. Volume1,843,110
30 Day Avg. Volume1,654,023
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥965.00Price Target Upside160.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-42.73
Revenue Forecast (FY)¥658.52M
Bulls Say, Bears Say
Bulls Say
Improved LeverageA materially lower debt-to-equity ratio meaningfully reduces structural financing risk and increases financial flexibility. Over the medium term this supports continued R&D investment and partner negotiations by lowering default risk and interest burden versus prior years.
Revenue Growth TrendConsistent, if modest, top-line growth across consecutive years indicates early commercial traction or expanding collaboration income. Sustained revenue increases help absorb fixed costs, improve operating leverage potential, and form a foundation for longer-term margin improvement if scaled.
Partnering/licensing-focused ModelA business model emphasizing partnerships and licensing is durable for development-stage biotech: it can accelerate product reach, share commercialization costs, and reduce capital intensity. Structurally this lowers sole-commercialization risk and can convert pipeline value into revenue without full internal buildout.
Bears Say
Deep UnprofitabilityPersistent negative gross, operating, and net margins indicate the current cost base far exceeds revenue scale. Over months, this constrains reinvestment capacity, undermines path to self-sustaining operations, and increases dependence on external funding or dilutive financing to maintain development activities.
High Cash BurnMaterial and worsening cash outflows create a structural financing need: persistent negative OCF and FCF force recurring capital raises or partnership monetization. That elevates dilution risk, can compress negotiation leverage with partners, and makes long-term program delivery contingent on securing new capital.
Negative Returns On EquitySustained negative ROE reflects inability to generate returns from invested capital, limiting the firm's capacity to attract non-dilutive financing and strategic investors. Structurally, this weak capital efficiency undermines long-term shareholder value unless profitability or partner-funded pathways emerge.
Healios KK News
4593 FAQ
What was Healios KK’s price range in the past 12 months?
Healios KK lowest stock price was ¥255.00 and its highest was ¥747.00 in the past 12 months.
What is Healios KK’s market cap?
Healios KK’s market cap is ¥46.44B.
When is Healios KK’s upcoming earnings report date?
Healios KK’s upcoming earnings report date is May 20, 2026 which is in 9 days.
How were Healios KK’s earnings last quarter?
Healios KK released its earnings results on Feb 16, 2026. The company reported ¥18.9 earnings per share for the quarter, beating the consensus estimate of ¥4.65 by ¥14.25.
Is Healios KK overvalued?
According to Wall Street analysts Healios KK’s price is currently Undervalued.
Does Healios KK pay dividends?
Healios KK does not currently pay dividends.
What is Healios KK’s EPS estimate?
Healios KK’s EPS estimate is -11.14.
How many shares outstanding does Healios KK have?
Healios KK has 135,002,200 shares outstanding.
What happened to Healios KK’s price movement after its last earnings report?
Healios KK reported an EPS of ¥18.9 in its last earnings report, beating expectations of ¥4.65. Following the earnings report the stock price went up 4.087%.
Which hedge fund is a major shareholder of Healios KK?
Currently, no hedge funds are holding shares in JP:4593
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Healios KK
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
4593 Stock 12 Month Forecast
Average Price Target
¥965.00
▲(160.81% Upside)
Technical Analysis
SanBio Co
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---